A few days later, GLP-1 drug rival Novo Nordisk announced that four out of five dose strengths of its GLP-1 obesity drug Wegovy (0.5 mg, 1 mg, 1.7 mg and 2.4 mg) are now available in the US
While the label lists common side effects and the potential for significant harm, such as an increased risk of thyroid C-cell tumors, pancreatitis, ileus, and diabetic retinopathy
S-Acetyl L-Glutathione concentrates heavily in your liver and lungs, where glutathione plays critical roles in healthy detoxification and respiratory function
Mild to moderate nausea is common when starting this medication and often improves with time
2019;42(Suppl 1):S90102
Additionally, the FDA has issued safety alerts about compounded or unapproved GLP-1 formulations, emphasizing that patients exposed to these off-label products face unpredictable and potentially serious side effects